You are here

CSL

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

Clinical Trials Arena

Mon, 02/12/24 - 10:20 am

clinical trials

myocardial infarction

CSL and Arcturus’ Covid-19 booster found to prolong immunity

Clinical Trials Arena

Tue, 02/6/24 - 09:26 am

Arcturus Therapeutics

clinical trials

CSL gets top-line boost thanks to a post-pandemic boom in plasma collections

Fierce Pharma

Wed, 08/16/23 - 11:14 pm

See which pharma brands are the strongest and fastest-growing in 2023

Medical Marketing and Media

Wed, 07/12/23 - 11:12 pm

Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte

Endpoints

Wed, 03/29/23 - 04:16 pm

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

Drugs.com

Wed, 03/1/23 - 10:07 am

clinical trials

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

BioSpace

Tue, 02/21/23 - 10:00 am

Big pharma’s new year catalysts

EP Vantage

Mon, 12/19/22 - 11:05 am

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Forbes

Mon, 12/5/22 - 10:48 am

10 Massachusetts Biopharma Companies Hiring Now

BioSpace

Fri, 12/2/22 - 11:18 am

Moderna Therapeutics

Intellia Therapeutics

Alloy Therapeutics

Werewolf Therapeutics

Sherlock Biosciences

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Medical Marketing and Media

Thu, 12/1/22 - 10:34 am

uniQure, CSL claim first okay for hemophilia B gene therapy

Pharmaphorum

Wed, 11/23/22 - 07:53 am

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Thu, 11/3/22 - 11:02 am

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Pharmaphorum

Wed, 11/2/22 - 10:15 am

CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies

Endpoints

Wed, 09/14/22 - 09:32 am

CSL reports Phase III data for garadacimab to treat hereditary angioedema

Clinical Trials Arena

Thu, 08/18/22 - 12:30 pm

clinical trials

hereditary angiodema

CSL Launches New Unified Global Brand Identity

BioSpace

Thu, 08/11/22 - 10:45 am

After delay, CSL's $11.7B deal for Vifor poised to close next week

Fierce Pharma

Tue, 08/2/22 - 10:39 am

CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb

Endpoints

Thu, 06/9/22 - 10:23 am

drug manufacturing

Pages